Shots:
CSPC to receive a $27M up front & will also be eligible to receive ~$148M in development and regulatory milestones, ~$1.0B in commercial milestones along with royalties on net sales. Elevation Oncology will be responsible to develop and commercialize EO-3021 in all global territories outside of Greater China
The collaboration will expand the pipeline to include two clinical stage precision oncology products & will use Elevation Oncology’s expertise in genomically defined cancers incl. those with Claudin18.2 overexpression
SYSA1801 is currently being studied in the P-I dose-escalation trial for CSPC in China & is expected to initiate a P-I clinical trial in the US in 2023
Ref: PRNewswire | Image: Elevation Oncology
